Recombinant Erythropoietin Market, By Drug Type, By Application, By Distribution Channel, By Geography

Description

The global recombinant erythropoietin market size was valued at US$ 7.01 billion in 2023 and is expected to reach US$ 8.68 billion by 2030, grow at a compound annual growth rate (CAGR) of 3.1% from 2023 to 2030.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 7.01 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	3.10%	2030 Value Projection:	US$ 8.68 Bn

Figure 1. Global Recombinant Erythropoietin Market Share (%), by Region, 2023

Recombinant Erythropoietin Market - IMG1

Recombinant erythropoietin is a bioengineered version of a naturally occurring hormone, erythropoietin, which is produced by the kidneys to stimulate the production of red blood cells. This recombinant version is produced in a laboratory, typically using genetically modified bacteria or mammalian cells. Recombinant erythropoietin is used primarily to treat anemia, particularly in individuals with chronic kidney disease or undergoing chemotherapy for cancer. It works by stimulating the bone marrow to produce more red blood cells, thereby increasing the oxygen-carrying capacity of the blood.

Recombinant erythropoietin (rEPO) is a revolutionary medical development that has transformed the treatment of anemia and related conditions. Erythropoietin is a hormone naturally produced by the kidneys, stimulating the production of red blood cells (RBC) in the bone marrow. Recombinant DNA technology has made it possible to produce synthetic erythropoietin in the laboratory, resulting in the creation of rEPO. This has provided has provided a highly effective approach to managing anemia, particularly in patients with chronic kidney diseases, cancer, and certain genetic disorders. By administering rEPO, healthcare professionals can stimulate RBC production, improve oxygen-carrying capacity, and alleviating symptoms of anemia, such as fatigue and weakness. Furthermore, rEPO has demonstrated significant benefits in reducing the need for blood transfusions and enhancing quality of life for patients. The widespread adoption of recombinant erythropoietin has revolutionized anemia management and continues to play a crucial role in various medical fields.

Market Dynamics:

The rising prevalence of chronic diseases such as chronic kidney disease (ckd) and cancer is anticipated to drive growth of the global recombinant erythropoietin market over the forecast period. For instance, according to data published on January 12, 2023, by John Wiley & Sons, Inc., a publishing company, in 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the U.S.

However, stringent regulatory requirements, safety concerns, side effects, and reimbursement challenges are expected to hamper growth of the global recombinant erythropoietin market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the global recombinant erythropoietin market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global recombinant erythropoietin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Biocon Limited, LG Chem Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Celltrion Inc., 3SBio Inc., BioSidus SA, Astellas Pharma Inc, and Lotus Pharmaceutical Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global recombinant erythropoietin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant erythropoietin market

Detailed Segmentation:

By Drug Type:
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
By Application:
- Cancer
- Hematology
- Renal diseases
- Neurology
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Amgen Inc.
- Johnson & Johnson (Janssen Pharmaceuticals)
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Novartis AG
- Biocon Limited
- LG Chem Ltd.
- Intas Pharmaceuticals Ltd.
- Dr. Reddy's Laboratories Ltd.
- Celltrion Inc.
- 3SBio Inc.
- BioSidus SA
- Astellas Pharma Inc
- Lotus Pharmaceutical Co., Ltd

Product Code: CMI5960

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Recombinant Erythropoietin, By Drug Type
- Market Recombinant Erythropoietin, By Application
- Market Recombinant Erythropoietin, By Distribution Channel
- Market Recombinant Erythropoietin, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising prevalence of chronic kidney disease (ckd)
- Restraints
Stringent Regulatory Requirements
- Opportunities
Emerging Markets
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Recombinant Erythropoietin Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Recombinant Erythropoietin Market , By Drug Type, 2018-2030, (US$ billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Epoetin-alfa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Epoetin-beta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Darbepoetin-alfa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)

6. Recombinant Erythropoietin Market, By Application, 2018-2030, (US$ billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Hematology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Renal diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Neurology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)

7. Recombinant Erythropoietin Market , By Distribution Channel, 2018-2030, (US$ billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)

8. Recombinant Erythropoietin Market , By Region, 2018-2030, (US$ billion)

Introduction
- Market Share Analysis, By Country, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2019-2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- 2018 - 2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 - 2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Amgen Inc.

Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
- Johnson & Johnson (Janssen Pharmaceuticals)
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Pfizer Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- F. Hoffmann-La Roche AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Novartis AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Biocon Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- LG Chem Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Intas Pharmaceuticals Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Dr. Reddy's Laboratories Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Celltrion Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- 3SBio Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- BioSidus SA
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Astellas Pharma Inc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
- Lotus Pharmaceutical Co., Ltd
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views

10. Section

Research Methodology
About us